One-carbon Therapeutics AB is a privately held company incorporated in Sweden

Late-stage preclinical development

The company focuses on the late-stage preclinical development of its lead candidate targeting MTHFD1/2, preparing for the phase I trial in 2024. We are also expanding our discovery and developing pipeline with new assets against novel targets.

Our mission

Turning cutting-edge scientific discoveries into first-in-class therapies that have the potential to make dramatic improvements in the quality of life and survival of patients.

Our Team

Our team has extensive experience in oncology, drug discovery, and development. We are inspired by science and committed to delivering better precision medicines to patients